@article {Barnard2021.12.15.21267858, author = {Rosanna C. Barnard and Nicholas G. Davies and Carl A. B. Pearson and Mark Jit and W. John Edmunds}, title = {Projected epidemiological consequences of the Omicron SARS-CoV-2 variant in England, December 2021 to April 2022}, elocation-id = {2021.12.15.21267858}, year = {2021}, doi = {10.1101/2021.12.15.21267858}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The Omicron B.1.1.529 SARS-CoV-2 variant was first detected in late November 2021 and has since spread to multiple countries worldwide. We model the potential consequences of the Omicron variant on SARS-CoV-2 transmission and health outcomes in England between December 2021 and April 2022, using a deterministic compartmental model fitted to epidemiological data from March 2020 onwards. Because of uncertainty around the characteristics of Omicron, we explore scenarios varying the extent of Omicron{\textquoteright}s immune escape and the effectiveness of COVID-19 booster vaccinations against Omicron, assuming the level of Omicron{\textquoteright}s transmissibility relative to Delta to match the growth in observed S gene target failure data in England. We consider strategies for the re-introduction of control measures in response to projected surges in transmission, as well as scenarios varying the uptake and speed of COVID-19 booster vaccinations and the rate of Omicron{\textquoteright}s introduction into the population. These results suggest that Omicron has the potential to cause substantial surges in cases, hospital admissions and deaths in populations with high levels of immunity, including England. The reintroduction of additional non-pharmaceutical interventions may be required to prevent hospital admissions exceeding the levels seen in England during the previous peak in winter 2020{\textendash}2021.Competing Interest StatementRCB, NGD, MJ and WJE are participants of the UK{\textquoteright}s Scientific Pandemic Influenza Group on Modelling (SPI-M). WJE attends the UK{\textquoteright}s Scientific Advisory Group for Emergencies. All authors declare no competing interests.Funding StatementThe following funding sources are acknowledged as providing funding for the named authors. This project has received funding from the European Union{\textquoteright}s Horizon 2020 research and innovation programme - project EpiPose (101003688: RCB, MJ, WJE) and the UK Medical Research Council (MC_PC_19065: NGD, WJE). It was also partly funded by the Bill \& Melinda Gates Foundation (INV-003174 and INV-016832: MJ) and the National Institute for Health Research (NIHR) (Health Protection Research Unit for Immunisation NIHR200929: NGD, MJ; Health Protection Research Unit in Modelling and Health Economics NIHR200908: MJ, WJE; PR-OD-1017-20002: WJE). CABP is supported by the Bill \& Melinda Gates Foundation (OPP1184344) and the UK Foreign, Commonwealth and Development Office (FCDO)/Wellcome Trust Epidemic Preparedness Coronavirus research programme (ref. 221303/Z/20/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this research was given by the London School of Hygiene \& Tropical Medicine Ethics Committee, project ID: 22828.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sources used for these analyses are either publicly available, or were provided to RCB and NGD as members of the UK{\textquoteright}s Scientific Pandemic Influenza Modelling (SPI-M) group, which provides expert advice to the UK{\textquoteright}s Department of Health and Social Care and wider UK government on scientific matters. Specific permissions have been sought to use SPI-M data for this publication. The SPI-M datasets used for model fitting are unpublished and not publicly available, but are closely aligned with the UK Government{\textquoteright}s COVID-19 dashboard (see https://coronavirus.data.gov.uk/) and other publicly available sources such as the Wellcome Sanger Institute{\textquoteright}s COVID-19 genomic surveillance data (see https://covid19.sanger.ac.uk/downloads).}, URL = {https://www.medrxiv.org/content/early/2021/12/16/2021.12.15.21267858}, eprint = {https://www.medrxiv.org/content/early/2021/12/16/2021.12.15.21267858.full.pdf}, journal = {medRxiv} }